Single Center, Randomized, Placebo-Controlled Trial to Establish Maximum Tolerated Dose, Optimal Titration Schedule, Safety, Tolerability, and Pharmacokinetics of Org 26576 in Patients Diagnosed With Major Depressive Disorder

Trial Profile

Single Center, Randomized, Placebo-Controlled Trial to Establish Maximum Tolerated Dose, Optimal Titration Schedule, Safety, Tolerability, and Pharmacokinetics of Org 26576 in Patients Diagnosed With Major Depressive Disorder

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Sep 2014

At a glance

  • Drugs ORG 26576 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Biomarker
  • Sponsors Organon; Schering-Plough
  • Most Recent Events

    • 07 Jun 2012 Results reported at the 28th International Congress of Cellegium Internationale Neuro-Psychopharmacologicum.
    • 28 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 28 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top